Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 27

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 27
---
 for the April 2025 Warrants or Pre-Funded Warrants.

There is no established public trading market for the April 2025 Warrants or Pre-Funded Warrants offered hereby, and we do not expect a market to develop. In addition, we do not intend to apply to list the April 2025 Warrants or Pre-Funded Warrants on any national securities exchange or other nationally recognized trading system, including Nasdaq. Without an active market, the liquidity of those securities will be limited.

The April 2025 Warrants in this offering are speculative in nature.

Following this offering, the market value of the April 2025 Warrants, if any, is uncertain and there can be no assurance that the market value of the April 2025 Warrants will equal or exceed their imputed public offering price. In the event that our Common Stock price does not exceed the exercise price of the April 2025 Warrants during the period when such April 2025 Warrants are exercisable, such April 2025 Warrants may not have any value. Furthermore, each April 2025 Warrant will expire five years from its date of issuance.

Except as set forth in the April 2025 Warrants and Pre-Funded Warrants, Holders of the April 2025 Warrants and Pre-Funded Warrants will not have rights of holders of our shares of Common Stock until such April 2025 Warrants and Pre-Funded Warrants are exercised.

Except as set forth in the April 2025 Warrants and Pre-Funded Warrants the April 2025 Warrants and Pre-Funded Warrants in this offering do not confer any rights of share ownership on their holders, but rather merely represent the right to acquire shares of our Common Stock at a fixed price. Until holders of April 2025 Warrants and Pre-Funded Warrants acquire shares of our Common Stock upon exercise of the April 2025 Warrants and Pre-Funded Warrants, as applicable, holders of April 2025 Warrants and Pre-Funded Warrants will have no rights with respect to our shares of Common Stock underlying such April 2025 Warrants and Pre-Funded Warrants.

| 10 |

Weare required to obtain Warrant Stockholder Approval prior to exercise of the April 2025 Warrants and until we are able to receive such approval the April 2025 Warrants will not be exercisable. If we are unable to obtain such approval the April 2025 Warrants will have no